Whitepaper

Asia - New Frontier
As the pharmaceutical market experiences rapid growth in Asia, more clinical trials are being conducted in the region, offering new opportunities for the biopharma. Offshore clinical trial development offers several advantages to both U.S. and European firms—larger patient populations than the West resulting in faster recruitment rates, regional expertise, overcoming local regulatory hurdles, meeting global regulatory requirements etc . Studies conducted in Asia have also been shown to be more cost-effective, particularly in the area of patient enrollment.

Click here to download the white paper